Bunzl expects 2025 profit in line with forecasts as profit margins stabilise

Bunzl reaffirmed its April guidance for adjusted operating profit for 2025, forecasting group revenue growth of 2–3% at constant exchange rates (broadly flat on reported rates) with the lift coming from acquisitions while underlying organic revenue remains flat, and an adjusted operating margin around 7.6%. Margin deterioration moderated in H2 thanks to improved performance in North America and Continental Europe, easier comparatives and Nisbets synergies; the group completed the October acquisition of Damito (€14m revenue in 2024) and a £200m share buyback, and expects year‑end leverage just over 2.0x. Management expects a return to organic growth in 2026 and will pursue further cost actions to support a more stable profit outlook, though operating margin is expected to be slightly down year‑on‑year.

Analysis

Bunzl has reaffirmed its April guidance for adjusted operating profit for 2025, forecasting group revenue growth of 2–3% at constant exchange rates while reporting broadly flat revenue on actual rates and an adjusted operating margin of around 7.6%. The company points to acquisitions as the primary growth lever—highlighted by the October purchase of Damito (€14m revenue in 2024)—while underlying organic revenue is flat and a margin decline seen in H1 has moderated in H2. Management completed a £200m share buyback for 2025 and expects year‑end leverage to be just over 2.0x, implying continued balance‑sheet flexibility despite capital returns.

Operationally, margin stabilization was supported by performance improvements in North America and Continental Europe, easier comparatives and synergy benefits from Nisbets, and management reports new business wins in North America. Frank van Zanten describes the market as "challenging" but expects a return to organic growth in 2026, with ongoing cost actions to support a more stable profit outlook while warning that the operating margin is expected to be slightly down year‑on‑year. The reliance on acquisitions for near‑term growth and the modest scale of Damito underline that organic recovery is the principal near‑term catalyst.

Investor implications center on execution and cash generation: the buyback reduces shares and supports EPS but leaves leverage at c.2.0x, so integration execution, organic revenue inflection and margin trends will determine upside. Key risks are a delayed organic recovery or renewed margin pressure; the current market signal is mildly positive but cautious given flat organic volumes and planned slight margin decline next year.

Key Decisions for Investors

• Maintain a neutral to modestly positive stance and consider accumulating on meaningful weakness because management has confirmed 2025 guidance and completed a £200m buyback that supports EPS,
• Monitor quarterly organic revenue, adjusted operating margin and synergy delivery from Nisbets/Damito closely as primary catalysts for upside; tighten stops or reduce exposure if organic growth does not show improvement by mid‑2026,
• Use leverage and free‑cash‑flow metrics as triggers for action—if year‑end leverage moves materially above 2.5x or free cash flow weakens versus guidance, consider trimming positions to limit downside